News about "Lupin Limited"

Lupin Receives US FDA Approval for Interchangeable Biosimilar Ranibizumab, Ranluspec

Lupin has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, expanding its biosimilars portfolio and broadening access to treatments for retinal and vision-related disorders.

Lupin Limited | 05/06/2026 | By News Bureau

Lupin and Natco Secure USFDA Approval for Generic Cancer Drug Eribulin Mesylate Injection

Lupin and Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic equivalent of Halaven, used in the treatment of advanced breast cancer and liposarcoma.

Lupin Limited | 03/06/2026 | By News Bureau

Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development

Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.

Lupin Limited | 29/05/2026 | By News Bureau

Lupin Launches Diabetes Drug Combination in the US

Lupin launches dapagliflozin and metformin extended-release tablets in the US, offering a bioequivalent and cost-effective alternative for type 2 diabetes management.

Lupin Limited | 22/04/2026 | By News Bureau |  125

Lupin Limited Receives USFDA EIR for Goa Manufacturing Facility

Lupin Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its manufacturing facility in Goa. The report follows a recent inspection of the site and marks the formal closure of the regulatory review process.

Lupin Limited | 01/03/2026 | By Darshana |  164

Lupin Limited partners with Spektus Pharma to commercialize DeslaFlex in Canada

Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialize DeslaFlex, a novel antidepressant, in Canada.

Lupin Limited | 16/02/2026 | By Darshana |  154

Lupin Launches Dasatinib Tablets in USA Following FDA Approval

Lupin Limited has announced the launch of dasatinib tablets in multiple strengths in the United States following approval of its Abbreviated New Drug Application from the USA Food and Drug Administration.

Lupin Limited | 03/02/2026 | By Darshana |  251

Lupin acquires brands ONDERO, ONDERO MET brand from Boehringer Ingelheim

Lupin acquires brands ONDERO, ONDERO MET brand from Boehringer Ingelheim

Lupin Limited | 21/08/2023 | By Sudeep Soparkar |  813

Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations

Lupin’s Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations

Lupin Limited | 14/08/2023 | By Sudeep Soparkar |  918

Lupin receives tentative approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Lupin receives tentative approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Lupin Limited | 24/07/2023 | By Sudeep Soparkar |  689